

Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Community
Ask the community for help and clear up your study doubts
Discover the best universities in your country according to Docsity users
Free resources
Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors
RAC Device Practice Question Set 11- US
Typology: Quizzes
1 / 3
This page cannot be seen from the preview
Don't miss anything!
Question Answer Explanation A company wants to export a device that has not received FDA approval but is legal in Europe. What document is needed? A) Certificate to Foreign Government B) Certificate of Exportability C) 510(k) Clearance D) PMA Approval B) Certificate of Exportability Explanation: Devices not FDA-approved but meeting foreign standards require a Certificate of Exportability (Section 801(e)(1) of the FD&C Act). When can an IRB waive informed consent for a clinical trial? A) If the trial presents minimal risk and meets ethical criteria B) Never, it is always required C) Only if the FDA allows it D) When requested by the sponsor A) If the trial presents minimal risk and meets ethical criteria Explanation: Under 21 CFR 56.109, IRBs can waive consent if the study poses minimal risk and obtaining consent is impractical. Under the FDA's Good Clinical Practice (GCP) guidelines, what must be documented in clinical trials? A) Only the statistical analysis plan B) Only the recruitment strategies used C) All aspects of the trial, including data, participant consent, and adverse events D) Only the results of the clinical trial C) All aspects of the trial, including data, participant consent, and adverse events When multiple facilities are involved in a Class III device's design, assembly or processing, the PMA holder should do all of the following EXCEPT: A. Ensure the quality systems in all facilities are in compliance with 21 CFR 820 regulations, as applicable B. Include in the PMA submission a complete description of the device's manufacturing, processing, packing, storage and installation methods C. Provide written authorization to reference the Device Master File information from a contracted facility D. Submit quality system information only for the facility involved in the design of the device D. Submit quality system information only for the facility involved in the design of the device
A company is submitting a PMA for a permanent implant. The company has performed biocompatibility testing based on ISO requirements and believes the package is complete. Which of the following testing does the company absolutely need to demonstrate long-term safety of its device: A. Intracutaneous irritation B. Genotoxicity C. Acute toxicity D. Carcinogenicity D. Carcinogenicity A company is planning to launch its new List B (Annex II) IVD. Which of the following actions should the regulatory professional recommend to the company? A. Obtain Notified Body approval of the technical documentation and the quality system B. CE mark the device using the "self-certification" route C. Ensure that the Notified Body conducts batch release and examination of the dossier design D. Conduct performance evaluation in accordance with common technical specifications A. Obtain Notified Body approval of the technical documentation and the quality system Here's why: List B (Annex II) IVDs under the IVDD (In Vitro Diagnostic Directive 98/79/EC) require Notified Body involvement. The manufacturer cannot self-certify. A. Obtain Notified Body approval of the technical documentation and the quality system: This is the core requirement for List B IVDs. The Notified Body assesses the technical documentation and the manufacturer's quality system to ensure compliance. B. CE mark the device using the "self-certification" route: This is incorrect for List B IVDs. Self-certification is primarily for general IVDs, not those on Annex II. C. Ensure that the Notified Body conducts batch release and examination of the dossier design: Batch release is more common for List A IVDs, which carry a higher risk. List B devices require a review of the technical documentation and quality system. D. Conduct performance evaluation in accordance with common technical specifications: While performance evaluation is crucial and often required, it is a component of the technical documentation that the Notified Body reviews. It is not the overall action the regulatory professional would recommend. The primary action is the Notified Body review.